Enphase Energy Inc vs Novavax Inc — how do they compare? Enphase Energy Inc trades at $41.6 (market cap $5.81B), while Novavax Inc trades at $8.22 (market cap $1.39B). The key difference: Enphase Energy Inc is far larger — about 4.2× Novavax Inc's market cap. Which is the better fit depends on your goals.
| ENPH | NVAX | |
|---|---|---|
Market Cap | $5.81B | $1.39B |
Sector | Technology | Health |
52-Week High | $72.33 | $11.19 |
52-Week Low | $26.12 | $6.22 |
Enterprise Value | $5.46B | $890.94M |
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $41.59, down 7.55% in the past 24 hours, reflecting recent bearish pressure. The stock shows a mixed technical picture with support near $39 and resistance at $44, while fundamentals indicate solid profitability with a 44.23% gross margin and consistent earnings beats in recent quarters. Recent news highlights product expansions in Europe and Australia, alongside positive analyst coverage citing long-term tailwinds despite short-term challenges.
Outlook remains cautiously optimistic with a consensus price target of $42.79, slightly above current levels. Key opportunities include global product rollouts and high margins, but risks involve revenue volatility, competitive pressures, and ongoing legal scrutiny. Investors should weigh strong fundamentals against near-term stock weakness and market sentiment shifts.
Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.
The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.
Trailing returns across standard periods
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →